RAS signalling in the colorectum in health and disease

Cell Communication and Adhesion

Volumn 19, Issue 1, 2012, Pages 1-9

  Poulogiannis, George ^a   Luo, Feijun ^b,c   Arends, Mark J ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; G PROTEIN COUPLED RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR NRF2; WNT PROTEIN;

ALLELE; AMINO ACID SUBSTITUTION; APOPTOSIS; CELL PROLIFERATION; CODON; COLORECTAL CANCER; ENZYME ACTIVATION; GENE DELETION; GENE MUTATION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; WILD TYPE;

ANTIBODIES; COLON; COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAS PROTEINS; RECTUM; SIGNAL TRANSDUCTION;

EID: 84858808741     PISSN: 15419061     EISSN: 15435180     Source Type: Journal    
DOI: 10.3109/15419061.2011.649380     Document Type: Review

References (75)

1. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS (2009). Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 219: 435-445.
2. Akao Y, Nakagawa Y, Naoe T (2006). let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharmacuet Bull. 29: 903-906.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26: 1626-1634.
4. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen O P, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001). Kirsten ras mutations in patients with colorectal cancer: the ' RASCAL II' study. Br J Canc. 85: 692-696. (Pubitemid 32929467)
5. Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A (2007). Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Canc Res. 67: 8468-8476. (Pubitemid 47437420)
6. Barbacid M (1987). ras genes. Annu Rev Biochem. 56: 779-827.
7. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462: 108-112.
8. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, Dressman HK, West M, Nevins JR (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439: 353-357. (Pubitemid 43128862)
9. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Perez de Castro I, Li C, Thompson CB, Cox AD, Philips MR (2006). PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell. 21: 481-493. (Pubitemid 43228004)
10. Brosens RP, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N, Flens M, Meijer GA, Ylstra B (2010). Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol. 221: 411-424.
11. Castagnola P, Giaretti W (2005). Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta. 1756: 115-125. (Pubitemid 41773138)
12. Cobb MH, Goldsmith EJ (1995). How MAP kinases are regulated. J Biol Chem. 270: 14843-14846.
13. Cogoi S, Paramasivam M, Membrino A, Yokoyama KK, Xodo LE (2010). The KRAS promoter responds to Myc-associated zinc finger and poly(ADP-ribose) polymerase 1 proteins, which recognize a critical quadruplex-forming GA-element. J Biol Chem. 285: 22003-22016.
14. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11: 753-762.
15. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475: 106-109.
16. Downward J (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Canc. 3: 11-22. (Pubitemid 37328883)
17. Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell. 61: 759-767.
18. Fest T, Mougey V, Dalstein V, Hagerty M, Milette D, Silva S, Mai S (2002). c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene. 21: 2981-2990. (Pubitemid 34522897)
19. Fukasawa K, Vande Woude GF (1997). Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol. 17: 506-518. (Pubitemid 26425640)
20. Gao JS, Zhang Y, Tang X, Tucker LD, Tarwater PM, Quesenberry PJ, Rigoutsos I, Ramratnam B (2011). The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett. 585: 693-699.
21. Goldfarb M, Shimizu K, Perucho M, Wigler M (1982). Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature. 296: 404-409. (Pubitemid 12108522)
22. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Canc Cell. 4: 111-120. (Pubitemid 37040827)
23. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T (2008). Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 40: 600-608. (Pubitemid 351601205)
24. Hall A, Marshall CJ, Spurr NK, Weiss RA (1983). Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature. 303: 396-400. (Pubitemid 13094876)
25. Harvey JJ (1964). An unidentified virus which causes the rapid production of tumours in mice. Nature. 204: 1104-1105.
26. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002). A central role for JNK in obesity and insulin resistance. Nature. 420: 333-336. (Pubitemid 35398190)
27. Janssen KP, el-Marjou F, Pinto D, Sastre X, Rouillard D, Fouquet C, Soussi T, Louvard D, Robine S (2002). Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology. 123: 492-504. (Pubitemid 34827194)
28. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005). RAS is regulated by the let-7 microRNA family. Cell. 120: 635-647. (Pubitemid 40343076)
29. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359: 1757-1765.
30. Katz ME, McCormick F (1997). Signal transduction from multiple Ras effectors. Curr Opin Genet Dev. 7: 75-79. (Pubitemid 27092767)
31. Kinzler KW, Vogelstein B (1996). Lessons from hereditary colorectal cancer. Cell. 87: 159-170. (Pubitemid 26358996)
32. Krens LL, Baas JM, Gelderblom H, Guchelaar HJ (2010). Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today. 15: 502-516.
33. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 105: 3903-3908. (Pubitemid 351723497)
34. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME (2003). A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 114: 323-334. (Pubitemid 36962931)
35. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem. 274: 7936-7940.
36. Li YC, Chen CR, Chang EC (2000). Fission yeast Ras1 effector Scd1 interacts with the spindle and affects its proper formation. Genetics. 156: 995-1004.
37. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008). Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9: 962-972.
38. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ (2011). Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 4: ra17.
39. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ (2007). Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice. Oncogene. 26: 4415-4427. (Pubitemid 47014468)
40. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ (2009). Mutated K-rasAsp12 promotes tumourigenesis in ApcMin mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol. 90: 558-574.
41. Luo F, Poulogiannis G, Ye H, Hamoudi R, Arends MJ (2011a). Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis. Oncol Rep. 26: 125-133.
42. Luo F, Poulogiannis G, Ye H, Hamoudi R, Zhang W, Dong G, Arends MJ (2011b). Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability. J Pathol. 223: 390-399.
43. Luo F, Ye H, Hamoudi R, Dong G, Zhang W, Patek CE, Poulogiannis G, Arends MJ (2010). K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colo-nic adenoma formation. J Pathol. 220: 542-550.
44. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 137: 835-848.
45. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IA (1995). Evidence for cell-specific differences in transformation by N-, H-and K-ras. Oncogene. 11: 1639-1647.
46. Malumbres M, Barbacid M (2003). RAS oncogenes: the first 30 years. Nat Rev Canc. 3: 459-465. (Pubitemid 37328850)
47. McCormick F (1999). Signalling networks that cause cancer. Trends Cell Biol. 9: M53-M56.
48. Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, Suzuki H, Idogawa M, Kashima L, Yanagihara K, Fujita M, Hosokawa M, Kusano M, Sabau SV, Tatsumi H, Imai K, Shinomura Y, Tokino T (2009). A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Canc. 9: 198.
49. Muslin AJ (2008). MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 115: 203-218.
50. Naguib A, Wilson CH, Adams DJ, Arends MJ (2011). Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signal. 6: 2.
51. Nakao M, Kawauchi S, Uchiyama T, Adachi J, Ito H, Chochi Y, Furuya T, Oga A, Sasaki K (2011). DNA copy number aberrations associated with the clinicopathological features of colorectal cancers: Identification of genomic biomarkers by array-based comparative genomic hybridization. Oncol Rep. 25: 1603-1611.
52. Ohnishi T, Tomita N, Monden T, Ohue M, Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, Monden M (1997). A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Canc. 75: 341-347. (Pubitemid 27051047)
53. Orecchia R, Infusini E, Sciutto A, Rapallo A, Di Vinci A, Nigro S, Geido E, Giaretti W (2000). Ki-ras activation in vitro affects G1 and G2M cell-cycle transit times and apoptosis. J Pathol. 190: 423-429. (Pubitemid 30163581)
54. Osterop AP, Medema RH, Bos JL, vd Zon GC, Moller DE, Flier JS, Moller W, Maassen JA (1992). Relation between the insulin receptor number in cells, autophosphorylation and insulin-stimulated Ras.GTP formation. J Biol Chem. 267: 14647-14653.
55. Otori K, Oda Y, Sugiyama K, Hasebe T, Mukai K, Fujii T, Tajiri H, Yoshida S, Fukushima S, Esumi H (1997). High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut. 40: 660-663. (Pubitemid 27278336)
56. Plowman SJ, Berry RL, Bader SA, Luo F, Arends MJ, Harrison DJ, Hooper ML, Patek CE (2006). K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J Exp Clin Cancer Res. 25: 259-267. (Pubitemid 44113872)
57. Poulogiannis G, Ichimura K, Hamoudi RA, Luo F, Leung SY, Yuen ST, Harrison DJ, Wyllie AH, Arends MJ (2010). Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol. 220: 338-347.
58. Pulciani S, Santos E, Lauver AV, Long LK, Robbins KC, Barbacid M (1982). Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci USA. 79: 2845-2849. (Pubitemid 12032329)
59. Ravingerova T, Barancik M, Strniskova M (2003). Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem. 247: 127-138. (Pubitemid 36798517)
60. Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW (2006). MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Canc Res. 66: 6598-6605. (Pubitemid 44085615)
61. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA (2000). The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene. 19: 3948-3954. (Pubitemid 30658985)
62. Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V, Jamieson TJ, Guerra C, Ashton GH, Barbacid M, Clarke AR (2006). Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci (USA). 103: 14122-14127. (Pubitemid 44452990)
63. Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, Haviv S, Asara JM, Pandolf PP, Cantley LC (2011). Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal. 4: ra13.
64. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Dohner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 137: 821-834.
65. Segal M, Clarke DJ (2001). The Ras pathway and spindle assembly collide? Bioessays. 23: 307-310. (Pubitemid 32285754)
66. Shih C, Weinberg RA (1982). Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell. 29: 161-169.
67. Shimizu K, Goldfarb M, Perucho M, Wigler M (1983). Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc Natl Acad Sci USA. 80: 383-387. (Pubitemid 13174633)
68. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH (2011). miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Comm. 404: 896-902.
69. Shivapurkar N, Huang L, Ruggeri B, Swalsky PA, Bakker A, Finkelstein S, Frost A, Silverberg S (1997). K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Canc Lett. 115: 39-46. (Pubitemid 27139854)
70. Sullivan KM, Kozuch PS (2011). Impact of KRAS mutations on management of colorectal carcinoma. Patholog Res Int. 2011: 219-309.
71. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T (2005). An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 37: 48-55. (Pubitemid 40070939)
72. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y (2002). E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell. 9:1017-1029. (Pubitemid 34626671)
73. Tsang WP, Kwok TT (2009). The miR-18a*microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 30: 953-959.
74. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 9: 1031-1044. (Pubitemid 34626672)
75. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA (2010). Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 120: 3940-3952.